PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Fleeman N, Bagust A, Boland A, et al. Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis. Southampton (UK): NIHR Journals Library; 2011 Dec. (Health Technology Assessment, No. 15.42.)

List of abbreviations

AE

adverse event

AG

Assessment Group

AI

aromatase inhibitor

ANA

anastrozole

ASCO

American Society of Clinical Oncology

AUC

area under the curve

CBR

clinical benefit rate

CEAC

cost-effectiveness acceptability curve

CI

confidence interval

CR

complete response

CRD

Centre for Reviews and Dissemination

CSR

clinical study report

ECOG

the European Cooperative Oncology Group

EGF30008

efficacy and safety of lapatinib combined with letrozole trial

eLEcTRA

efficacy and safety of letrozole combined with trastuzumab trial

EMA

European Medicines Agency

EQ-5D

European Quality of Life-5 Dimensions

ER

oestrogen receptor

ER+

oestrogen receptor positive

EXE

exemestane

FACT

Functional Assessment of Cancer Therapy

FDA

the US Food and Drug Administration

FISH

fluorescence in situ hybridisation

HER2

human epidermal growth factor receptor 2

HER2+

human epidermal growth factor receptor 2 positive

HER2−

human epidermal growth factor receptor 2 negative

HR

hazard ratio

HR+

hormone receptor positive

HR−

hormone receptor negative

ICER

incremental cost-effectiveness ratio

IHC

immunohistochemistry

IPCW

inverse probability censoring weight

ITT

intention to treat

i.v.

intravenous

LAP

lapatinib

LET

letrozole

LVEF

left ventricular ejection fraction

LYG

life-year gained

mBC

metastatic breast cancer

MS

manufacturer's submission/manufacturers' submissions

NICE

National Institute for Health and Clinical Excellence

ORR

overall response rate

OS

overall survival

PD

progressive disease

PFLY

progression-free life-year

PFS

progression-free survival

PgR

progesterone receptor

PgR+

progesterone receptor positive

PP

per protocol

PPLY

post-progression life-years

PPS

post-progression survival

PR

partial response

PSA

probabilistic sensitivity analysis

PSS

Personal Social Services

QALY

quality-adjusted life-year

QoL

quality of life

RCT

randomised controlled trial

RPSFT

rank-preserving structural failure time

SAE

serious adverse event

SE

standard error

TAM

tamoxifen

TAnDEM

efficacy and safety of trastuzumab combined with anastrozole trial

TRA

trastuzumab

TTP

time to progression

All abbreviations that have been used in this report are listed here unless the abbreviation is well known (e.g. NHS), or it has been used only once, or it is a non-standard abbreviation used only in figures/tables/appendices, in which case the abbreviation is defined in the figure legend or in the notes at the end of the table.

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubReader format: click here to try
Cover of Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis
Lapatinib and Trastuzumab in Combination with an Aromatase Inhibitor for the First-Line Treatment of Metastatic Hormone Receptor-Positive Breast Cancer which Over-Expresses Human Epidermal Growth Factor 2 (HER2): A Systematic Review and Economic Analysis.
Health Technology Assessment, No. 15.42.
Fleeman N, Bagust A, Boland A, et al.
Southampton (UK): NIHR Journals Library; 2011 Dec.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...